U.S. Biomedical Advanced Research and Development Authority (BARDA) Taps ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
ICON plc (NASDAQ:ICLR) has announced a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to execute a clinical trial for next generation COVID-19 vaccine candidates. The trial will involve 10,000 subjects over a six-month period. BARDA will select the vaccine candidate for the trial, accelerating the start of the Phase 2b clinical trial.
September 13, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ICON plc's partnership with BARDA for a clinical trial of next-gen COVID-19 vaccines could potentially boost its profile and revenues if the trial is successful.
ICON plc's partnership with BARDA for a clinical trial of next-gen COVID-19 vaccines could potentially boost its profile and revenues if the trial is successful. The trial's success could lead to increased demand for ICON's services, potentially driving up its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100